cusatuzumab
Phase 2- Indications
- Acute Myeloid Leukemia
Company intelligence / Profile preview
RefinedScience uses advanced AI-enabled analytics on deeply curated disease-specific datasets to identify novel targets and biomarkers. Their approach enables smarter clinical trial designs that can revive stalled drugs by matching them with precise patient subpopulations. They have demonstrated proof of concept in AML leading to a spinout company OncoVerity. The company aims to reduce time and cost of drug development while increasing success rates.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on RefinedScience.